<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03001180</url>
  </required_header>
  <id_info>
    <org_study_id>CCHMC-LMI</org_study_id>
    <nct_id>NCT03001180</nct_id>
  </id_info>
  <brief_title>Identification of Biomarkers for Patients With Vascular Anomalies</brief_title>
  <official_title>Identification of Biomarkers for Patients With Vascular Anomalies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lymphangiomatosis and Gorham's Disease Alliance (LGDA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klippel Trenaunay (KT) Support Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CLOVES Syndrome Community Support Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will use blood (serum and plasma) and tissue obtained from participants undergoing&#xD;
      prescribed surgical resection of vascular anomalies of interest proposed in this study. The&#xD;
      study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank&#xD;
      maintained by the Department of Hematology/Oncology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While vascular anomalies are rare diseases, they can be life-threatening and devastating to&#xD;
      affected children and their families. Advances in diagnosis, monitoring and therapies will be&#xD;
      significantly improved if non-invasive biomarkers that are sensitive and specific can be&#xD;
      identified. Obtaining a tissue biopsy to help in diagnosis can actually worsen the disease&#xD;
      and so identification of specific blood biomarkers is highly desirable. Studies will measure&#xD;
      angiogenic factors in serum and plasma samples at baseline and on therapy. Tissue removed&#xD;
      during surgical resection or blood removed prior to sclerotherapy will be used to obtain&#xD;
      cells and tissue for the assessment of where biomarkers are coming from and to identify&#xD;
      disease-causing pathways for new therapeutic targeting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">January 2050</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of Biomarkers with Differential Diagnosis</measure>
    <time_frame>An Average of Every 2 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Biomarkers with Disease Severity</measure>
    <time_frame>An Average of Every 2 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Biomarkers with Response to Therapies</measure>
    <time_frame>An Average of Every 2 Years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Vascular Anomaly</condition>
  <condition>Generalized Lymphatic Anomaly</condition>
  <condition>Kaposiform Hemangioendothelioma</condition>
  <condition>Kaposiform Lymphangiomatosis</condition>
  <condition>Gorham-Stout Disease</condition>
  <condition>Klippel Trenaunay Syndrome</condition>
  <condition>Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue, Blood, Plasma, and Serum Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any participant having labs drawn as standard of care will have blood drawn for the study&#xD;
        if consented/assented. All participants who are undergoing a surgical procedure or&#xD;
        sclerotherapy are currently consented for participation in the tissue bank. The principle&#xD;
        investigator will be looking at tissue from these participants. There is no further&#xD;
        recruitment for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient having labs drawn as standard of care will have blood drawn for the study&#xD;
             if consented/ assented.&#xD;
&#xD;
          -  All patients who are undergoing a surgical procedure or sclerotherapy are currently&#xD;
             consented for participation in the tissue bank.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy LeCras, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy LeCras, PhD</last_name>
    <phone>5138034862</phone>
    <email>hvmcresearch@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Metcalf</last_name>
      <phone>513-803-2606</phone>
      <email>hvmcresearch@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Timothy LeCras, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrienne Hammill, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>December 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2016</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized Lymphatic Anomaly</keyword>
  <keyword>Vascular Anomaly</keyword>
  <keyword>Kaposiform Hemangioendothelioma</keyword>
  <keyword>Kaposiform Lymphangiomatosis</keyword>
  <keyword>Vascular Endothelial Growth Factor</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>GLA</keyword>
  <keyword>KLA</keyword>
  <keyword>KHE</keyword>
  <keyword>GSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Osteolysis, Essential</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

